Category: Latest News
-
Gold stays below $4,900/oz as rate outlook uncertainty weighs on safe-haven demand
Gold prices edged higher in Asian trading on Thursday but remained far from key levels as investors grappled with uncertainty surrounding interest rates and the potential inflationary consequences of the U.S.–Israel conflict with Iran. Stronger-than-expected U.S. producer price inflation data, along with the Federal Reserve’s warning that inflation may rise further, pushed gold lower on…
-
Oil and gas surge, Fed holds rates steady, Micron slips – key market drivers: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. stock futures moved lower on Thursday as escalating attacks on energy infrastructure in the Middle East pushed oil prices sharply higher. The Federal Reserve left its interest rate outlook unchanged, keeping open the possibility of a rate cut later this year, although Fed Chair Jerome Powell cautioned investors not to rely too heavily on…
-
One of Africa’s most prolific gold districts — the Lake Victoria Gold Fields
This is The Capital Compass. Today we’re heading to one of Africa’s most prolific gold districts — the Lake Victoria Gold Fields — to take a closer look at Cameo Resources (CSE:MEO) and its Katoro Project. This is a region that has attracted some of the world’s largest gold producers, and Cameo has assembled a…
-
Drone Warfare Reshapes NATO Priorities: Airbus, DroneShield, and NEO Battery Materials in Focus
DroneShield – Digital Defense Systems at the Heart of Modern Warfare Today’s theaters of war no longer resemble the battlefields of the Napoleonic era. Instead of thousands of soldiers, highly sensitive digital systems now face off against one another, using maximum reconnaissance and data consolidation to identify military targets and define the corresponding electronic chains…
-
Wall Street Slumps as Hawkish Pause and Inflation Fears Rattle Investors
U.S. equities faced a wave of selling on Wednesday as a “triple threat” of stubborn inflation data, escalating Middle East tensions, and a cautious Federal Reserve sent all three major indices deep into the red. The Dow Jones Industrial Average suffered its worst session of the year, shedding over 760 points as investors recalibrated their…
-
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading
InspireMD Inc. (NASDAQ:NSPR) reported stronger-than-expected fourth-quarter results for 2025, beating both earnings and revenue forecasts as sales accelerated following the U.S. launch of its CGuard Prime device. The company posted earnings per share of -$0.14 for the quarter, outperforming analyst expectations of -$0.19. Revenue reached $3.15 million, well above the forecast of $2.32 million. Following…
-
Lifeward shares fall after Q4 results miss expectations
Lifeward Ltd. (NASDAQ:LFWD) reported weaker-than-expected results for the fourth quarter of fiscal 2025, with both earnings and revenue coming in well below analyst forecasts. The disappointing performance sent the company’s shares down about 7% in premarket trading, with the stock changing hands near $7. The medical technology company reported earnings per share of -$2.85 for…
-
Akari Therapeutics to present ADC research at AACR Annual Meeting 2026
Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, one of the leading global conferences for cancer research. The company’s abstract will be featured as a poster presentation during the event, which will take place April 17–22, 2026. The presentation will…
-
Artelo Biosciences moves into glaucoma research with fully funded clinical study
Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San Diego–based clinical-stage biotech company said the investigator-sponsored trial will be fully funded through support from Glaucoma UK and the Health and Social Care (HSC) Research & Development Division,…
-
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs
Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the continued development of its epilepsy drug candidate OV329, including expanding research into seizures linked to tuberous sclerosis complex and infantile spasms. The biotechnology company, currently valued at about $262 million, has seen its shares climb roughly 337%…